Maria Grazia Valsecchi
Overview
Explore the profile of Maria Grazia Valsecchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
295
Citations
7154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cavalli A, De Vincentis A, Pedone C, Laudisio A, Santoro L, Ferrara M, et al.
BMC Geriatr
. 2025 Mar;
25(1):138.
PMID: 40025484
Background: Psychoactive drugs represent a major contributor to falls in older people. This study aims to evaluate the prescribing practice of psychoactive drugs in older people hospitalized for hip fracture...
2.
Valverde P, Velasquez T, Ortiz R, Fuentes-Alabi S, Pena A, Gonzalez J, et al.
Pediatr Blood Cancer
. 2025 Feb;
:e31616.
PMID: 39979582
Since 2000, centers across Central America have shared treatment guidelines for Wilms tumor, using histology (anaplasia present or absent) and tumor stage to stratify patients into low-, intermediate-, and high-risk...
3.
Braidotti S, Zudeh G, Franca R, Kiren V, Colombini A, Bettini L, et al.
Clin Transl Sci
. 2025 Feb;
18(2):e70136.
PMID: 39891427
High-dose methotrexate (HD-MTX) infusions are commonly used to consolidate remission in children with acute lymphoblastic leukemia (ALL). We investigate the potential role of candidate polymorphisms in SLCO1B1 (rs4149056 and rs2306283),...
4.
Rossi A, Romano R, Fecarotta S, DellAnno M, Pecorella V, Passeggio R, et al.
Med
. 2024 Nov;
:100544.
PMID: 39547230
Background: Mucopolysaccharidosis type VI (MPS VI) is due to a deficiency of the lysosomal enzyme arylsulfatase B (ARSB) that results in multi-organ accumulation of glycosaminoglycans (GAGs). Limitations of current treatments...
5.
Cavasin D, Zanini U, Montelisciani L, Valsecchi M, Fabbri L, Antolini L, et al.
Monaldi Arch Chest Dis
. 2024 Oct;
PMID: 39410827
COVID-19 has a negative impact on the survival of respiratory patients, especially those with interstitial lung disease. This review aims to better understand the effect of COVID-19 on patients with...
6.
Ammirati E, Varrenti M, Sormani P, Bernasconi D, Moro C, Grosu A, et al.
Int J Cardiol
. 2024 Sep;
417():132567.
PMID: 39299393
Background: Identifying markers associated with adverse events after acute myocarditis (AM) is relevant to plan follow-up. We assessed the prognostic performance of previously described cardiac magnetic resonance imaging (CMRI) markers...
7.
De Carlis R, Lauterio A, Schlegel A, Gringeri E, Patrono D, Camagni S, et al.
Liver Transpl
. 2024 Sep;
31(1):70-84.
PMID: 39287560
Dual hypothermic oxygenated perfusion (DHOPE) is increasingly being used to extend liver preservation to improve transplant logistics. However, little is known about its benefits in high-risk liver grafts. This study...
8.
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort
Soria A, Graziano F, Ghilardi G, Lapadula G, Dalla Gasperina D, Benatti S, et al.
Heliyon
. 2024 Sep;
10(16):e36102.
PMID: 39247344
Objective: Monoclonal antibodies (mAbs) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) reduced Coronavirus Disease 2019 (COVID-19) hospitalizations in people at risk of clinical worsening. Real-world descriptions are limited. Methods:...
9.
Conter V, Valsecchi M, De Lorenzo P, Gandemer V, Heyman M, Saha V, et al.
Haematologica
. 2024 Jul;
109(11):3766-3770.
PMID: 39021218
No abstract available.
10.
Lecornec N, Fahd M, De Lorenzo P, Valsecchi M, Micalizzi C, Diaz P, et al.
Br J Haematol
. 2024 Jul;
205(3):1230-1233.
PMID: 38982637
No abstract available.